COVID-19 Diagnosis and Risk of Death Among Adults With Cancer in Indiana: Retrospective Cohort Study

Nimish Valvi1*, MPH, MBBS, DrPH; Hetvee Patel2, MS; Giorgos Bakoyannis2, PhD; David A Haggstrom3,4,5, MD, MAS; Sanjay Mohanty4, MD; Brian E Dixon1,2,3*, MPA, PhD

1Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, United States
2Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, United States
3Center for Health Information and Communication, Health Services Research & Development Service, Richard L. Roudebush VA Medical Center, Veterans Health Administration, Indianapolis, IN, United States
4Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, United States
5Center for Health Services Research, Regenstrief Institute, Indianapolis, IN, United States
*these authors contributed equally

Corresponding Author:
Brian E Dixon, MPA, PhD
Richard M. Fairbanks School of Public Health
Indiana University
1050 Wishard Boulevard, Floors 5 and 6
Indianapolis, IN, 46202-2872
United States
Phone: 1 3172783072
Email: bedixon@regenstrief.org

Abstract

Background: Prior studies, generally conducted at single centers with small sample sizes, found that individuals with cancer experience more severe outcomes due to COVID-19, caused by SARS-CoV-2 infection. Although early examinations revealed greater risk of severe outcomes for patients with cancer, the magnitude of the increased risk remains unclear. Furthermore, prior studies were not typically performed using population-level data, especially those in the United States. Given robust prevention measures (eg, vaccines) are available for populations, examining the increased risk of patients with cancer due to SARS-CoV-2 infection using robust population-level analyses of electronic medical records is warranted.

Objective: The aim of this paper is to evaluate the association between SARS-CoV-2 infection and all-cause mortality among recently diagnosed adults with cancer.

Methods: We conducted a retrospective cohort study of newly diagnosed adults with cancer between January 1, 2019, and December 31, 2020, using electronic health records linked to a statewide SARS-CoV-2 testing database. The primary outcome was all-cause mortality. We used the Kaplan-Meier estimator to estimate survival during the COVID-19 period (January 15, 2020, to December 31, 2020). We further modeled SARS-CoV-2 infection as a time-dependent exposure (immortal time bias) in a multivariable Cox proportional hazards model adjusting for clinical and demographic variables to estimate the hazard ratios (HRs) among newly diagnosed adults with cancer. Sensitivity analyses were conducted using the above methods among individuals with cancer-staging information.

Results: During the study period, 41,924 adults were identified with newly diagnosed cancer, of which 2894 (6.9%) tested positive for SARS-CoV-2. The population consisted of White (n=32,867, 78.4%), Black (n=2671, 6.4%), Hispanic (n=832, 2.0%), and other (n=5554, 13.2%) racial backgrounds, with both male (n=21,354, 50.9%) and female (n=20,570, 49.1%) individuals. In the COVID-19 period analysis, after adjusting for age, sex, race or ethnicity, comorbidities, cancer type, and region, the risk of death increased by 91% (adjusted HR 1.91; 95% CI 1.76-2.09) compared to the pre–COVID-19 period (January 1, 2019, to January 14, 2020) after adjusting for other covariates. In the adjusted time-dependent analysis, SARS-CoV-2 infection was associated with an increase in all-cause mortality (adjusted HR 6.91; 95% CI 6.06-7.89). Mortality increased 2.5 times among adults aged 65 years and older (adjusted HR 2.74; 95% CI 2.26-3.31) compared to adults 18-44 years old, among male (adjusted HR 1.23; 95% CI 1.14-1.32) compared to female individuals, and those with ≥2 chronic conditions (adjusted HR 2.12; 95% CI 1.88-2.39).
Introduction

As of July 2022, there have been over 1 million deaths from COVID-19 in the United States [1]. Certain patient subgroups, such as older adults, as well as individuals with chronic conditions such as hypertension, diabetes, and chronic lung diseases, have been shown to be at increased risk of morbidity and mortality due to COVID-19 [2]. Given immunosuppression due to both disease and treatment among patients with cancer, there exists increasing risks among patients with cancer who have COVID-19, require hospitalization and intensive care, and are at risk of death [3-5].

As a precaution because of increasing transmission, cancer care providers made sweeping changes to the management of patients with cancer at the start of the pandemic, with changes to radiation therapy sessions, immunotherapy, and administration of oral medications instead of intravenous chemotherapy [6-9]. These changes were introduced based on early evidence, primarily drawn from outside the United States. Early studies from China [10-12] reported a 2- to 4-fold increase in mortality due to COVID-19 among patients with cancer compared to those without cancer, while a few smaller studies reported a case-fatality rate of 29% [13] and poorer outcomes [3] among patients with cancer who have COVID-19. Some studies from Europe and the United States have investigated mortality among cancer subpopulations and demonstrated a 34% [14] increase among individuals with solid tumors compared to hematologic tumors. A retrospective cohort study from the United States found a 2.5-fold increase in hospitalizations among patients with hematologic tumors compared to solid tumors and a 67% increase in hospitalization among adults 65 years and older compared to those 65 years and younger [15].

Prior studies in the United States were generally conducted at single institutions, most with small sample sizes that focused on case-fatality rates [4,16]. Some of the larger studies conducted in the United Kingdom evaluated case fatality rates [17] and cross-sectionally compared all-cause mortality among individuals with active cancer treatment [18,19]. However, these studies did not report negative outcomes because of anticancer therapies, suggesting mortality is driven by demographic factors and comorbidities [18,19]. Furthermore, prior studies [4,12,15,20] generally examined in populations with COVID-19 severe disease following infection with the SARS-CoV-2 virus. These studies were important to our understanding of the novel COVID-19 as they were conducted within the first 6 months of the pandemic. Now that more than 2 years have passed since the start of the pandemic, it is important to conduct larger retrospective analyses to better understand risks of COVID-19 on mortality among individuals with cancer. As additional protections against COVID-19 become widespread, such as effective vaccines for individuals with immunosuppressive conditions [21-26], patients with cancer should be aware of their risks to make informed choices about prevention and treatment.

The objective of this study is to estimate risk of SARS-CoV-2 infection and death in a large, statewide cohort of adults recently diagnosed with cancer. This study is unique in its use of a population approach to estimating risk, as opposed to earlier studies from a single institution or network of hospitals in a city or region. The study is further unique in its use of infection-based risk rather than examining patients who present for care to a clinic or hospital. Comprehensive cancer diagnosis captured from electronic medical records linked to governmental, hospital-based, and private SARS-CoV-2 testing centers enabled robust data capture for examining population-level risk.

Methods

Overview

We conducted a retrospective cohort study of all individuals aged 18 years and older with a recent diagnosis of cancer. Data were extracted from Regenstrief Institute’s Indiana Network for Patient Care (INPC). The INPC [27], developed almost 30 years ago, is among the largest regional health information exchange (HIE) networks and contains over 17 million patient-level medical records. Medical records served as the source for identifying cancer diagnoses using the International Classification of Diseases, 10th Revision codes in the population. Moreover, due to its role in supporting population-level surveillance during the COVID-19 pandemic [28,29], the INPC medical records are linked to governmental, hospital, and private SARS-CoV-2 testing data from across the state. The integrated data set provided comprehensive information on cancer diagnosis along with SARS-CoV-2 infection during the entire study period. This includes information on positive SARS-CoV-2 individuals with cancer who did not present for medical care (eg, asymptomatic individuals and individuals with mild symptoms). The INPC further contains information from death certificates (eg, date of death) provided by the Indiana Department of Health. This enabled determination of death status among individuals who were not treated for COVID-19 in a hospital setting.
All individuals 18 years and older, with an incident of cancer diagnosis between January 1, 2019, and December 31, 2020, were included for this study. Individuals with a prior history of cancer (e.g., diagnosis before January 1, 2019) were excluded. Because INPC diagnoses date back to 2011 for most institutions, the data source possessed sufficient documentation of prior cancer diagnosis and treatment. In keeping with practice guidelines, individuals were deemed to have COVID-19 if a reverse transcription polymerase chain reaction assay test from a throat or nose swab was positive for the SARS-CoV-2 virus. Participants with a clinical or radiological diagnosis of COVID-19 without the reverse transcription polymerase chain reaction test were not included in this study. This report is based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies [30].

Covariates

Covariates for the study included demographic and clinical variables obtained from the INPC. The demographic variables were age groups in years (18-44, 45-64, and ≥65), sex, race or ethnicity (White, Black, Hispanic, and other), and region of residence (rural or urban). The region of residence was defined based on the Rural-Urban Commuting Area codes [31]. The clinical variables were number of chronic diseases, cancer types, and staging. The number of chronic disease variable was categorized as (“0,” “1,” and “≥2”), and cancer types were classified according to International Classification of Diseases, 10th Revision codes (Table S5 in Multimedia Appendix 1). The “Other” category included cancers of the bone and articular tissue, endocrine glands, central nervous system, mesothelioma and soft tissue, male reproductive organs (excluding prostate), and female reproductive organs. The “Other digestive” cancer group included esophagus, stomach, small intestine, liver and intrahepatic bile ducts, gall bladder, and pancreas. Individuals with nonmelanoma skin cancers were excluded from the study [17,18]. The list of chronic diseases, obtained from prior studies [10,17,18], included hypertension, diabetes, coronary heart disease, chronic kidney disease, cerebrovascular disease, hepatitis, and chronic obstructive pulmonary disease.

Staging information was captured using natural language processing from free text within the clinical notes stored in the INPC. We used nDepth, a natural language processing tool developed at the Regenstrief Institute to extract tumor-node-metastasis concepts from oncology notes provided by the comprehensive cancer centers in Indiana to the INPC. The work was developed from previous research and validated in early studies [32-35]. The cancer-staging variable was classified as I, II, III, and IV based on the tumor-node-metastasis classification [36].

Exposure

We included time from cancer diagnosis to SARS-CoV-2 infection as a time-dependent variable as the first exposure variable. We further divided time as a binary variable defined as COVID-19 period, where the pre–COVID-19 (January 1, 2019, to January 14, 2020) period was coded as 0 and the COVID-19 period (January 15, 2020, to December 31, 2020) was coded as 1.

Outcome

The primary endpoint was all-cause mortality, which was evaluated between January 1, 2019, and December 31, 2020. All individuals who were alive on December 31, 2020, were considered as right-censored observations in this analysis.

Ethical Considerations

Study approval was obtained from the Indiana University Institutional Review Board (Exempt Protocol #2009667926). Informed consent was waived due to retrospective use of preexisting, deidentified data from medical records.

Statistical Analysis

Descriptive statistics of baseline demographic and clinical characteristics are presented in Table 1. The distributions for cumulative proportion of survival over time for age group, sex, race or ethnicity, comorbidities, and COVID-19 diagnosis were estimated using Kaplan-Meier method (Figures 1-5).

The study period started from January 1, 2019, and follow-up ended at death or at the end of the study period on December 31, 2020. In this approach, we compared mortality during the COVID-19 period (January 15, 2020, to December 31, 2020) with that of the pre–COVID-19 period (January 1, 2019, to January 14, 2020). We allowed for pre–COVID-19 period follow-up of survivors to be censored on January 14, 2020, accounting for comparable average time to each event in each period. First, we estimated the survival function using the nonparametric Kaplan-Meier estimator for both the COVID-19 and the pre–COVID-19 period. Next, we estimated the effect of the COVID-19 period variable on all-cause mortality using a Cox proportional hazards model that adjusted for other demographic and clinical variables.

We assessed SARS-CoV-2 infection as a time-dependent exposure. We allocated time spent before a positive SARS-CoV-2 laboratory test to the group that did not have COVID-19 and time spent after the first positive SARS-CoV-2 laboratory test to the group that were confirmed to have COVID-19. This time-dependent approach reduces the immortal-time bias [37]. We estimated mortality hazard ratios (HRs) using time-dependent Cox proportional hazards models [38] adjusting for relevant covariates and assessing proportionality [39] assumptions with cumulative martingale residuals and the Supremum test.
Table 1. Characteristics of study cohort diagnosed with cancer during the pre–COVID-19 (January 1, 2019, to January 14, 2020) and COVID-19 (January 15, 2020, to December 31, 2020) periods—Indiana, 2019-2020 (N=41,924).

| Characteristics                                      | Pre–COVID-19 period | COVID-19 period | Total |
|------------------------------------------------------|---------------------|-----------------|-------|
|                                                      | Dead (n=18,895), n (%) | Dead (n=19,631), n (%) |       |
| Age range (years)                                     |                     |                 |       |
| 18-44                                                | 1638 (8.7)          | 1635 (8.3)      | 3389 (8.1) |
| 45-64                                                | 7005 (37.0)         | 7100 (36.2)     | 15,102 (36.0) |
| ≥65                                                  | 10,252 (88.3)       | 10,896 (55.5)   | 23,433 (55.9) |
| Race or ethnicity                                     |                     |                 |       |
| White                                                | 15,051 (79.6)       | 15,015 (74.2)   | 32,867 (78.4) |
| Black                                                | 1239 (6.6)          | 1173 (6.0)      | 2611 (6.4) |
| Hispanic                                             | 416 (2.2)           | 371 (1.9)       | 587 (1.4) |
| Other                                                | 2189 (11.6)         | 3072 (15.6)     | 5261 (12.2) |
| Sex                                                  |                     |                 |       |
| Female                                               | 9345 (49.5)         | 9725 (49.5)     | 20,570 (49.1) |
| Male                                                 | 9550 (50.5)         | 9906 (50.5)     | 21,354 (50.9) |
| Comorbidities                                         |                     |                 |       |
| 0                                                    | 13,863 (73.4)       | 14,567 (74.2)   | 28,430 (67.7) |
| 1                                                    | 3221 (17.0)         | 3313 (16.9)     | 6534 (15.6) |
| ≥2                                                   | 1811 (9.6)          | 1751 (8.9)      | 3562 (8.1) |
| Cancer                                               |                     |                 |       |
| Breast                                               | 2743 (14.5)         | 2919 (14.9)     | 5662 (13.5) |
| Colorectal                                            | 1391 (7.4)          | 1438 (7.3)      | 2829 (6.8) |
| Leukemia                                             | 665 (3.5)           | 714 (3.6)       | 1379 (3.3) |
| Lip, oral cavity, and pharynx                        | 415 (2.2)           | 466 (2.4)       | 881 (2.1) |
| Lung, trachea, and bronchus                          | 1629 (8.6)          | 1662 (8.5)      | 3291 (7.9) |
| Lymphoma                                             | 821 (4.3)           | 859 (4.4)       | 1680 (4.0) |
| Myeloma                                              | 411 (2.2)           | 328 (1.7)       | 739 (1.8) |
| Other hematological                                   | 97 (0.5)            | 89 (0.5)        | 186 (0.5) |
| Other digestive                                      | 1033 (5.5)          | 1139 (5.8)      | 2172 (5.2) |
| Prostate                                             | 2592 (13.7)         | 2729 (13.9)     | 5321 (12.6) |
| Skin (melanoma)                                      | 2734 (14.5)         | 2511 (12.8)     | 5245 (12.5) |
| Urinary tract                                         | 1270 (6.7)          | 1399 (7.1)      | 2669 (6.4) |
| Othera                                               | 3094 (16.4)         | 3378 (17.2)     | 6472 (15.5) |
| COVID-19 positive                                    |                     |                 |       |
| No                                                   | 17,545 (92.9)       | 18,346 (93.4)   | 39,891 (93.1) |
| Yes                                                  | 1350 (7.1)          | 1285 (6.5)      | 2635 (6.1) |
| Region                                               |                     |                 |       |
| Urban                                                | 14,436 (76.4)       | 14,222 (72.5)   | 28,658 (68.4) |
| Rural                                                | 4459 (23.6)         | 5409 (27.5)     | 9868 (22.6) |

aIncludes cancer types such as malignant neoplasia of the bone and articular tissue, endocrine glands, central nervous system, mesothelioma and soft
tissue, male reproductive organs (excluding prostate), and female reproductive organs.

**Figure 1.** Kaplan-Meier survival estimates of overall cancer population by age group (years), Indiana, 2019-2020.

**Figure 2.** Kaplan-Meier survival estimates of overall cancer population by sex, Indiana, 2019-2020.
Figure 3. Kaplan-Meier survival estimates of overall cancer population by race and ethnicity, Indiana, 2019-2020.

Figure 4. Kaplan-Meier survival estimates of overall cancer population by number of comorbidities, Indiana, 2019-2020.
Sensitivity Analysis
We further performed a sensitivity analysis with the 2 methods (time-dependent and COVID-19 period analysis) by additionally adjusting for cancer staging. The missingness of the staging variable was considered “missing not at random”; therefore, we performed the analysis on individuals who had the information on the cancer-staging variable. Baseline characteristics are found in Table S1 in Multimedia Appendix 1, COVID-19 period analysis is presented in Table S2 in Multimedia Appendix 1, and the time-dependent analysis from cancer to COVID-19 diagnosis is presented in Table S3 in Multimedia Appendix 1.
An additional time-dependent analysis was performed on individuals restricted to incident cancer cases from January 15, 2020, to December 31, 2020, to further reduce a possible immortal-time bias (Table S4 in Multimedia Appendix 1). All comparisons were 2-sided, and $P<.05$ was considered statistically significant. Analyses were conducted with SAS version 9.4 (SAS Institute).

Results
Cohort Characteristics
The study population consisted of 41,924 individuals with an incident diagnosis of cancer between January 1, 2019, and December 31, 2020 (Table 1). Of these, 2894 (6.2%) were laboratory-confirmed SARS-CoV-2 cases. Most cancer patients were white (n=32,867, 78.4%) and male (n=21,354, 50.9%). Approximately 1 in 5 (n=3221, 17.0%) patients with cancer possessed a single comorbid condition, and 1 in 10 (n=1811, 9.6%) had ≥2 comorbid conditions at the time of cancer diagnosis. Most patients were diagnosed with breast (n=5797, 13.8%), prostate (n=5468, 13.0%), and melanoma (n=5386, 12.8%) cancers during the study period.

All-Cause Mortality
During the study period, 3398 (8.1%) individuals died. In the COVID-19 period, there were 1324 (38.9%) deaths. Of the individuals who died in the COVID-19 period, 127 (9.6%) tested positive for SARS-CoV-2 (Table 1).

COVID-19 Period Analysis
The COVID-19 period analysis (Table 2) was adjusted for age group, sex, race or ethnicity, number of comorbidities, cancer type, and region of residence. Mortality was 91% higher during the COVID-19 period (adjusted HR 1.91; 95% CI 1.76-2.09; $P<.001$) compared to the pre–COVID-19 period. The risk of mortality among adults 65 years and older (adjusted HR 3.35; 95% CI 2.58-4.35; $P<.001$) compared to adults in the age group of 18-44 years. Risk of mortality among adults in rural residence (adjusted HR 0.99; 95% CI 0.91-1.09; $P=.87$) was 1% lower compared to urban residence, but it was not statistically significant.
Table 2. Unadjusted and adjusted Cox-regression analyses using landmarks during the pre–COVID-19 and COVID-19 periods as well as all-cause mortality—Indiana, 2019-2020 (N=41,924).

| Variable                        | Unadjusted                      | Adjusted                      | Unadjusted                      | Adjusted                      |
|---------------------------------|---------------------------------|-------------------------------|---------------------------------|-------------------------------|
|                                 | Estimate (SE) | Hazard ratio (95% CI) | P value | Estimate (SE) | Hazard ratio (95% CI) | P value |
| Covid-19 period<sup>a</sup>     |                  |                               |         |                  |                               |         |
| No                              | N/A<sup>b</sup> | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| Yes                             | 0.63 (0.04)    | 1.88 (1.73-2.05)           | <.001   | 0.65 (0.04)    | 1.91 (1.76-2.09)           | <.001   |
| Age group (years)               |                  |                               |         |                  |                               |         |
| 18-44                           | N/A             | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| 45-64                           | 0.91 (0.13)    | 2.48 (1.91-3.22)           | <.001   | 0.86 (0.13)    | 2.36 (1.81-3.08)           | <.001   |
| ≥65                             | 1.33 (0.13)    | 3.80 (2.94-4.91)           | <.001   | 1.20 (0.13)    | 3.35 (2.58-4.35)           | <.001   |
| Sex                             |                  |                               |         |                  |                               |         |
| Female                          | N/A             | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| Male                            | 0.16 (0.04)    | 1.17 (1.08-1.27)           | <.001   | 0.18 (0.04)    | 1.20 (1.10-1.30)           | <.001   |
| Race or ethnicity               |                  |                               |         |                  |                               |         |
| White                           | N/A             | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| Black                           | 0.13 (0.08)    | 1.14 (0.98-1.34)           | <.001   | 0.14 (0.08)    | 1.15 (0.98-1.34)           | <.001   |
| Hispanic                        | −0.74 (0.21)   | 0.48 (0.32-0.72)           | <.001   | −0.60 (0.21)   | 0.55 (0.36-0.83)           | <.001   |
| Other                           | −0.27 (0.07)   | 0.76 (0.66-0.87)           | <.001   | −0.20 (0.07)   | 0.82 (0.71-0.94)           | <.001   |
| Comorbidities                   |                  |                               |         |                  |                               |         |
| 0                               | N/A             | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| 1                               | 0.66 (0.05)    | 1.94 (1.76-2.15)           | <.001   | 0.39 (0.05)    | 1.48 (1.33-1.63)           | <.001   |
| ≥2                              | 1.20 (0.05)    | 3.31 (2.99-3.67)           | <.001   | 0.82 (0.05)    | 2.27 (2.04-2.52)           | <.001   |
| Cancer                          |                  |                               |         |                  |                               |         |
| Other                           | N/A             | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| Breast                          | −1.82 (0.12)   | 0.16 (0.13-0.21)           | <.001   | −1.72 (0.13)   | 0.17 (0.14-0.23)           | <.001   |
| Colorectal                      | −0.51 (0.09)   | 0.60 (0.50-0.72)           | <.001   | −0.61 (0.09)   | 0.54 (0.45-0.66)           | <.001   |
| Leukemia                        | 0.08 (0.09)    | 1.08 (0.89-1.32)           | <.001   | −0.03 (0.10)   | 0.96 (0.79-1.17)           | <.001   |
| Lip, oral cavity, and pharynx   | −0.52 (0.16)   | 0.59 (0.44-0.81)           | <.001   | −0.60 (0.16)   | 0.55 (0.40-0.75)           | <.001   |
| Lung and bronchus               | 0.59 (0.06)    | 1.82 (1.61-2.04)           | <.001   | 0.33 (0.06)    | 1.39 (1.23-1.57)           | <.001   |
| Lymphoma                        | −0.28 (0.11)   | 0.76 (0.61-0.93)           | <.001   | −0.29 (0.11)   | 0.74 (0.60-0.92)           | <.001   |
| Myeloma                         | −0.34 (0.15)   | 0.71 (0.52-0.96)           | <.001   | −0.53 (0.15)   | 0.58 (0.43-0.80)           | <.001   |
| Other digestive                 | 0.72 (0.06)    | 2.07 (1.82-2.35)           | <.001   | 0.53 (0.06)    | 1.69 (1.48-1.93)           | <.001   |
| Other hematological             | −1.63 (0.33)   | 0.41 (0.21-0.80)           | <.001   | −1.75 (0.58)   | 0.17 (0.06-0.54)           | <.001   |
| Prostate                        | −1.70 (0.12)   | 0.25 (0.21-0.30)           | <.001   | −1.94 (0.12)   | 0.14 (0.11-0.18)           | <.001   |
| Melanoma                        | −1.83 (0.13)   | 0.24 (0.20-0.28)           | <.001   | −1.93 (0.13)   | 0.14 (0.11-0.19)           | <.001   |
| Urinary tract                   | −0.52 (0.09)   | 0.67 (0.57-0.78)           | <.001   | −0.79 (0.09)   | 0.45 (0.37-0.55)           | <.001   |
| Region                          |                  |                               |         |                  |                               |         |
| Urban                           | N/A             | Reference                  | <.001   | N/A             | Reference                  | <.001   |
| Rural                           | 0.07 (0.04)    | 1.07 (0.98-1.17)           | <.001   | 0.007 (0.05)   | 0.99 (0.91-1.09)           | <.001   |

<sup>a</sup>Covid-19 period calculated as a binary variable; no=January 1, 2019, to January 14, 2020; yes=January 15, 2020, to December 31, 2020.

<sup>b</sup>N/A: not applicable.
**Time-Dependent Analysis**

After adjusting for age, race, sex, number of comorbidities, and cancer subtypes, SARS-CoV-2 infection was associated with a 7-fold increase in the hazard of death (adjusted HR 6.91; 95% CI 6.06-7.89; \( P < .001 \); Table 3). The hazard of death was 23% higher for male individuals (adjusted HR 1.23; 95% CI 1.14-1.32; \( P < .001 \)), compared to female individuals. All-cause mortality was higher by 45% in the lung cancer group (adjusted HR 1.45; 95% CI 1.31-1.61; \( P < .001 \)) and 80% in other digestive cancers group (adjusted HR 1.80; 95% CI 1.61-2.00; \( P < .001 \)), compared to other cancer types.
Table 3. Unadjusted and adjusted time-dependent (cancer diagnosis to COVID-19 diagnosis) Cox-regression analysis and all-cause mortality—Indiana, 2019-2020.

| Variable                        | Unadjusted                          | Adjusted                           |
|---------------------------------|-------------------------------------|-------------------------------------|
|                                 | Estimate (SE) | Hazard ratio (95% CI) | P value | Estimate (SE) | Hazard ratio (95% CI) | P value |
| Covid-19 diagnosis              |                        |                                    |         |              |                        |         |
| No                              | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| Yes                             | 1.87 (0.07)            | 6.53 (5.72-7.44)                  | 1.93 (0.07) | 6.91 (6.06-7.89) |
| Age group (years)               |                        |                                    |         |              |                        |         |
| 8-44                            | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| 45-64                           | 0.69 (0.09)            | 2.00 (1.65-2.42)                  | 0.65 (0.09) | 1.91 (1.57-2.32) |
| ≥65                             | 1.20 (0.09)            | 3.10 (2.54-3.70)                  | 1.01 (0.09) | 2.74 (2.26-3.31) |
| Sex                             |                        |                                    |         |              |                        |         |
| Female                          | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| Male                            | 0.19 (0.03)            | 1.21 (1.13-1.30)                  | 0.21 (0.04) | 1.23 (1.14-1.32) |
| Race or ethnicity               |                        |                                    |         |              |                        |         |
| White                           | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| Black                           | 0.11 (0.06)            | 1.12 (0.98-1.27)                  | 0.10 (0.06) | 1.11 (0.97-1.26) |
| Hispanic                        | −0.50 (0.15)           | 0.60 (0.45-0.81)                  | −0.47 (0.15) | 0.62 (0.46-0.84) |
| Other                           | −0.34 (0.06)           | 0.71 (0.63-0.80)                  | −0.23 (0.06) | 0.79 (0.70-0.90) |
| Comorbidities                   |                        |                                    |         |              |                        |         |
| 0                               | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| 1                               | 0.65 (0.04)            | 1.91 (1.75-2.07)                  | 0.37 (0.04) | 1.44 (1.33-1.57) |
| ≥2                              | 1.15 (0.04)            | 3.16 (2.90-3.43)                  | 0.75 (0.04) | 2.12 (1.94-2.31) |
| Cancer                          |                        |                                    |         |              |                        |         |
| Other                           | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| Breast                          | −1.51 (0.09)           | 0.22 (0.18-0.26)                  | −1.43 (0.09) | 0.24 (0.20-0.29) |
| Colorectal                      | −0.41 (0.07)           | 0.67 (0.57-0.78)                  | −0.51 (0.07) | 0.60 (0.51-0.70) |
| Leukemia                        | 0.03 (0.08)            | 1.03 (0.87-1.22)                  | −0.10 (0.09) | 0.90 (0.76-1.07) |
| Lip, oral cavity, and pharynx   | −0.31 (0.12)           | 0.73 (0.58-0.93)                  | −0.39 (0.12) | 0.67 (0.53-0.86) |
| Lung and bronchus               | 0.63 (0.05)            | 1.87 (1.69-2.07)                  | 0.38 (0.05) | 1.45 (1.31-1.61) |
| Lymphoma                        | −0.25 (0.09)           | 0.79 (0.66-0.94)                  | −0.31 (0.09) | 0.73 (0.61-0.87) |
| Myeloma                         | −0.24 (0.12)           | 0.78 (0.61-0.99)                  | −0.44 (0.12) | 0.64 (0.50-0.82) |
| Other digestive                 | 0.78 (0.05)            | 2.18 (1.96-2.43)                  | 0.58 (0.05) | 1.80 (1.61-2.00) |
| Other hematological             | −0.90 (0.33)           | 0.41 (0.21-0.78)                  | −1.06 (0.33) | 0.35 (0.18-0.67) |
| Prostate                        | −1.38 (0.09)           | 0.25 (0.21-0.30)                  | −1.64 (0.09) | 0.19 (0.16-0.23) |
| Melanoma                        | −1.43 (0.09)           | 0.24 (0.20-0.28)                  | −1.56 (0.09) | 0.21 (0.17-0.25) |
| Urinary tract                   | −0.39 (0.08)           | 0.67 (0.58-0.79)                  | −0.68 (0.08) | 0.50 (0.43-0.59) |
| Region                          |                        |                                    |         |              |                        |         |
| Urban                           | N/A                    | Reference                          | <.001   | N/A          | Reference              | <.001   |
| Rural                           | 0.13 (0.04)            | 1.14 (1.06-1.23)                  | 0.08 (0.04) | 1.09 (1.01-1.18) |

aN/A: not applicable.
Sensitivity Analysis

Finally, we assessed the impact of cancer-staging variable (n=9567) in a sensitivity analysis (Table S1 in Multimedia Appendix 1). Risk of death increased over 2.5-fold after SARS-CoV-2 infection (adjusted HR 2.55; 95% CI 2.17-2.99; P<.001) after adjusting for other covariates and the staging variable (Table S2 in Multimedia Appendix 1) in the COVID-19 period. In the time-dependent analysis, the hazard of death increased by 4.5-fold (adjusted HR 4.63; 95% CI 3.58-5.99) in the COVID-19 period compared to the pre–COVID-19 period, after adjusting for the other covariates and the staging variable (Table S3 in Multimedia Appendix 1).

Discussion

Principal Findings

In this large population-based study of individuals with recently diagnosed cancer, we found that SARS-CoV-2 infection negatively impacted survival with a 7-fold increase in death. Survival was largely impacted among adults with increasing age, those with 2 or more comorbid conditions, and among males. Individuals with lung cancer and other digestive cancers had the highest risk of death after SARS-CoV-2 infection. This analysis provides additional empirical evidence on the magnitude of risk to patients with cancer whose immune systems are often weakened either by the disease or treatment. This evidence may help providers and public health authorities take steps to improve outcomes among people with cancer, including messaging for vaccination campaigns as well as the need for continued vigilance against infection given continued waves of infection in the United States, Europe, and other nations.

Comparison With Prior Work

One of the notable findings from this study has been that SARS-CoV-2 infection shows a markedly increased risk of death in comparison to previous studies [10,11,14,15,17,40,41]. Previous case-control studies from China reported findings of 2-fold [10] and 3-fold [11] increases in all-cause mortality, which are much lower compared to our finding of a 7-fold increase in the time-dependent analysis. Multicenter cohort studies from Europe [14,18,40,41] and the United States [4,15,42] have reported similar findings on subgroups such as age, sex, and race. In retrospect, our statewide findings support the important policy decisions that were undertaken at the height of the pandemic of limiting exposure of SARS-CoV-2 for the general population and for individuals with cancer and other immunocompromised populations. However, some of these measures diverted resources to control the spread of the virus and reduced cancer screening access with a short drop in cancer diagnosis [43]. In comparison to the general population, our prevalence of SARS-CoV-2 (n=2894, 6.2%) in this study was substantially lower compared to the general population (17.9%) [44] in Indiana. Thus, showing that the cancer population likely took preventive measures to avoid exposure to the SARS-CoV-2 virus.

Our finding of increased mortality in individuals with lung cancer and other digestive cancers can partly explain the increased mortality among males. This increased mortality for lung cancers could be related to the underlying disease (eg, bronchial carcinoma) or due to coronaviruses that cause severe lung injury [45] observed during the SARS-CoV-1 outbreak in 2003 [46]. It may also be related to underlying health behaviors, including smoking [47], which is also associated with lung cancer. We found significantly lower mortality among hematological malignancies compared to the other solid tumors such as lung, digestive, and breast cancer. This contrasts with a multicenter study [14] in Europe and the United States, which found 40% increased odds in mortality for hematological cancers (such as lymphoma, leukemia, and myeloma) compared to solid tumors. This rather contradictory result may be explained by the fact that the prior study [14] grouped the cancers into three broader categories such as hematological, solid, and multiple cancers, which differ from our cancer variable that includes individual cancer types. Our population-based analysis enabled sufficient power for more granular analysis of individual cancer types compared with prior work.

In comparison to similar studies [4,14-16,18] of cancer cohorts, we accounted for time, which better explains the increased hazard due to SARS-CoV-2 infection. Thus, the increased hazard from our study highlights the need to further continue the care planning and conversations with family on treatment options, vaccinations, and SARS CoV-2 testing during treatment [14,15]. Recent findings demonstrate that individuals with compromised immune systems, including patients with cancer, do not have a strong protection from COVID-19 after full vaccination (eg, 2 doses of mRNA vaccine) [24-26]. Therefore, both the US Centers for Disease Control and Prevention and the US Food and Drug Administration recommend patients who have cancer and are receiving mRNA COVID-19 vaccines should receive 3 doses and a booster, practice nonpharmaceutical interventions, and, if infected, be monitored closely and considered early for proven therapies that can prevent severe outcomes [25,48].

The strengths of the study include that we were able to account for time to diagnosis of SARS-CoV-2 infection, which was a limitation for prior studies due to the nature of a global crisis. Second, we were able to account for individuals with cancer and without COVID-19, which places our findings in better context compared with previous studies that reported findings only among individuals with cancer and a COVID-19 diagnosis. Third, we were able to leverage data from a large statewide HIE representative of the underlying population, which supports generalization of findings to cancer populations compared to single institutions or multicenter studies in more narrow geographic regions. For example, one-third of Indiana’s population lives in rural areas, and the HIE accesses electronic health records from community hospitals in addition to 3 large regional cancer care providers in the state. Therefore, our findings strengthen the justification of treatment planning and care guidelines required for the management of patients with cancer, which were highlighted in prior studies.

Limitations

There are some limitations in our study. First, our analysis is dependent on the testing and reporting of SARS-CoV-2 from different facilities. This could underreport total COVID-19 cases.
in patients with cancer; however, this bias would be only toward those individuals who never received testing, given the HIE is linked to statewide testing databases. Early in the pandemic, however, testing was limited to symptomatic individuals. This could have led to testing among those with only severe COVID-19, thereby overestimating severity. Second, we were unable to account for COVID-19 severity and treatment confounders in our study; however, from previous studies, we know that treating the underlying cancer and with regular testing were prudent choices in either initiating or continuing with cancer treatment. In addition, cancer diagnoses [49-53] were ascertained via diagnostic codes, which introduces known measurement errors in terms of positive and negative predictive value. Lastly, the impact of the pandemic led to a substantial reduction in new cancer diagnosis and health services across the US [43,54] and globally [55-57], which might have overestimated the HR for our study.

**Conclusion**

In summary, this large study among individuals with cancer and SARS-CoV-2 emphasizes the need for continuing testing and monitoring patients for the delivery of oncology services. Given the risk of severe disease and mortality is substantially larger for patients who have cancer, the study further underscores the need for patients with cancer to receive complete vaccination, including recommended booster doses authorized by the Food and Drug Administration as well as Centers for Disease Control and Prevention.

**Acknowledgments**

This study was funded, in part, by the Indiana University Simon Cancer Center through a pilot grant. BED and NV are also supported by a contract from the Centers for Disease Control and Prevention (75D30120C07986) to study COVID-19 vaccine effectiveness. The funders did not have a role in reviewing or editing this manuscript.

The authors further thank the staff at the Regenstrief Institute, including Heidi Hosler, Lauren R Lembcke, and Anna R Roberts, for their role in data management and study logistics.

**Conflicts of Interest**

None declared.

**Multimedia Appendix 1**

Supplemental tables.

[DOCX File, 41 KB-Multimedia Appendix 1]

**References**

1. COVID-19 dashboard. Center for Systems Science and Engineering (CSSE). URL: https://coronavirus.jhu.edu/map.html [accessed 2021-07-15]
2. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). World Health Organization. URL: https://bit.ly/3EI19rF [accessed 2022-09-29]
3. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 Mar;21(3):335-337 [FREE Full text] [doi: 10.1016/S1470-2045(20)30096-6] [Medline: 32066541]
4. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020 Aug;31(8):1088-1089 [FREE Full text] [doi: 10.1016/j.annonc.2020.04.006] [Medline: 32330541]
5. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020 Jul 01;6(7):1108-1110 [FREE Full text] [doi: 10.1001/jamaoncol.2020.0980] [Medline: 32211820]
6. Clinical guide for the management of non-coronavirus patients requiring acute treatment: cancer. National Health Service. URL: https://www.nice.org.uk/media/default/about/covid-19/specialty-guides/cancer-and-covid-19.pdf [accessed 2020-10-26]
7. Cancer patient management during the COVID-19 pandemic. European Society for Medical Oncology. URL: https://www.esmo.org/guidelines/cancer-patientmanagement-during-the-covid-19-pandemic [accessed 2020-10-26]
8. Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. How we treat patients with lung cancer during the SARS-CoV-2 pandemic. ESMO Open 2020 Apr;5(2):e000765 [FREE Full text] [doi: 10.1136/esmoopen-2020-000765] [Medline: 32245904]
9. Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw 2020 Mar 20;18:693-701. [doi: 10.6004/jnccn.2020.7560] [Medline: 32197238]
10. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020 Jun;10(6):783-791 [FREE Full text] [doi: 10.1158/2159-8290.CD-20-0422] [Medline: 32345594]
11. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020 Jul;21(7):904-913 [FREE Full text] [doi: 10.1016/S1470-2045(20)30310-7] [Medline: 32479787]

12. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol 2020 Jun 10;13(1):75 [FREE Full text] [doi: 10.1186/s12050-020-00907-0] [Medline: 32522278]

13. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020 Jul;31(7):894-901 [FREE Full text] [doi: 10.1016/annonc.2020.03.296] [Medline: 32224151]

14. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, COVID-19 Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (Cancer [CC19]): a cohort study. Lancet 2020 Jun 20;395(10241):1907-1918 [FREE Full text] [doi: 10.1016/S0140-6736(20)31187-9] [Medline: 32473681]

15. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020 Aug 24;26(8):1218-1223 [FREE Full text] [doi: 10.1038/s41591-020-0979-0] [Medline: 32581332]

16. Mehta V, Goel S, Kabarriri R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov 2020 Jul;10(7):935-941 [FREE Full text] [doi: 10.1158/2159-8290.CD-20-0516] [Medline: 32359994]

17. Lee LYW, Cazier J, Starkey T, Briggs SEW, Arnold R, Bisht V, UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020 Oct;21(10):1309-1316 [FREE Full text] [doi: 10.1016/S1470-2045(20)30442-3] [Medline: 32853557]

18. Lee LY, Cazier J, Angelis V, Arnold R, Bisht V, Campton NA, UK Coronavirus Monitoring Project Team, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020 Jun 20;395(10241):1919-1926 [FREE Full text] [doi: 10.1016/S0140-6736(20)31173-9] [Medline: 32473682]

19. Vârnia C, Palles C, Arnold R, Curley H, Purshouse K, Cheng V, UKCCMP Team. Mortality Among Adults With Cancer Undergoing Chemotherapy or ImmunoTherapy and Infected With COVID-19. JAMA Netw Open 2022 Feb 01;5(2):e220130 [FREE Full text] [doi: 10.1001/jamanetworkopen.2022.0130] [Medline: 35188551]

20. Rassen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess deaths associated with COVID-19, by age and race and ethnicity - United States, January 26-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020 Oct 23;69(42):1522-1527 [FREE Full text] [doi: 10.15585/mmwr.mm6942e2] [Medline: 33090978]

21. Baden LR, El Sahly HM, Eweb E, Kotloff K, Frey S, Novak R, COVE Study Group. Efficacy and Safety of the mRNA-1273 COVID-19 Vaccine. N Engl J Med 2021 Feb 04;384(5):403-416 [FREE Full text] [doi: 10.1056/NEJMoa2035389] [Medline: 33378609]

22. Polack FP, Thomas SJ, Kitchens N, Absalon J, Gurtman A, Lockhart S, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2021 Dec 31;385(27):2603-2615 [FREE Full text] [doi: 10.1056/NEJMoa2035477] [Medline: 33301246]

23. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021 Jan 09;397(10269):99-111 [FREE Full text] [doi: 10.1016/S0140-6736(20)32661-1] [Medline: 33069889]

24. So ACP, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, et al. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers (Basel) 2021 Jul 16;13(14):3573 [FREE Full text] [doi: 10.3390/cancers13143573] [Medline: 34298785]

25. Embi PJ, Levy ME, Naleway AL, Patel P, Gagliani M, Natarajan K, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep 2021 Nov 05;70(44):1553-1559 [FREE Full text] [doi: 10.15585/mmwr.mm7044e3] [Medline: 34735426]

26. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022 Mar 18;71(7):255-263 [FREE Full text] [doi: 10.15585/mmwr.mm7107e2] [Medline: 35176007]

27. McDonnell CJ, Overhage JM, Barnes M, Schadow G, Blevins L, Dexter PR, INPC Management Committee. The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. Health Aff (Millwood) 2005 Sep;24(5):1214-1220. [doi: 10.1377/hlthaff.24.5.1214] [Medline: 16162565]

28. Dixon BE, Grannis SJ, McAndrews C, Broyles AA, Mikels-Carrasco W, Wiensch A, et al. Leveraging data visualization and a statewide health information exchange to support COVID-19 surveillance and response: Application of public health
29. Dixon BE, Grannis SJ, Lembcke LR, Valvi N, Roberts AR, Embi PJ. The synchronicity of COVID-19 disparities: Statewide epidemiologic trends in SARS-CoV-2 morbidity, hospitalization, and mortality among racial minorities and in rural America. PLoS One 2021;16(7):e0255063 [doi: 10.1371/journal.pone.0255063] [Medline: 34297747]

30. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 2014 Dec;12(12):1495-1499 [FREE text] [doi: 10.1016/j.ijsu.2014.07.013] [Medline: 25046131]

31. Economic Research Service. US Department of Agriculture. URL: https://www.ers.usda.gov [accessed 2022-09-29]

32. Mehrabi S, Krishnan A, Roch AM, Schmidt H, Li D, Kesterson J, et al. Identification of Patients with Family History of Pancreatic Cancer—Investigation of an NLP System Portability. Stud Health Technol Inform 2015;216:604-608 [FREE Full text] [Medline: 26262122]

33. Weiner M, Dexter PR, Heitthoff K, Roberts AR, Liu Z, Griffith A, et al. Identifying and Characterizing a Chronic Cough Cohort Through Electronic Health Records. Chest 2021 Jun;159(6):2346-2355. [doi: 10.1016/j.chest.2020.12.011] [Medline: 33345951]

34. Li X, Yu S, Zhang Z, Radican L, Cummins J, Engel SS, et al. Predictive modeling of hypoglycemia for clinical decision support in evaluating outpatients with diabetes mellitus. Curr Med Res Opin 2019 Nov;35(11):1885-1891. [doi: 10.1080/03007995.2019.1636016] [Medline: 31234649]

35. Imler TD, Sherman S, Imperiale TF, Xu H, Ouyang F, Beesley C, et al. Provider-specific quality measurement for ERCP using natural language processing. Gastroint Endosc 2018 Jan;87(1):164-173.e2 [FREE Full text] [doi: 10.1016/j.gie.2017.04.030] [Medline: 28476375]

36. Denoix P. Cancer In French West Africa: Cumulative Results of Ten Years Enquiry (1940-1949). Bull Inst Nat Hyg 1950;53(5):372-377.

37. Gail MH. Does cardiac transplantation prolong life? A reassessment. Ann Intern Med 1972 May 01;76(5):815-817. [doi: 10.7326/0003-4819-76-5-815] [Medline: 4554414]

38. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society: Series B (Methodological) 2018 Dec 05;34(2):187-202. [doi: 10.1111/bjs.1972.tb00899.x]

39. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993;80(3):557-572. [doi: 10.1093/biomet/80.3.557]

40. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020 Mar 12;323(18):1775-1776. [doi: 10.1001/jama.2020.4683] [Medline: 32203977]

41. Pinato DJ, Lee AJX, Biello F, Seguí E, Aguilar-Company J, Carbó A, et al. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers (Basel) 2020 Jul 08;12(7):1841 [FREE Full text] [doi: 10.3390/cancers12071841] [Medline: 32650523]

42. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Risk Factors for Mortality in Patients with COVID-19 in New York City. J Gen Intern Med 2021 Jan;36(1):17-26 [FREE Full text] [doi: 10.1007/s11606-020-05983-z] [Medline: 32607928]

43. Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform 2020 Nov;4:1059-1071 [FREE Full text] [doi: 10.1200/CCI.20.00134] [Medline: 33253013]

44. Yianoutsos CT, Halverson PK, Menachemi N. Bayesian estimation of SARS-CoV-2 prevalence in Indiana by random testing. Proc Natl Acad Sci U S A 2021 Feb 02;118(5):e2013906118 [FREE Full text] [doi: 10.1073/pnas.2013906118] [Medline: 33441440]

45. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020 Apr 23;382(17):1953-1966. [doi: 10.1056/nejmsr2005760] [Medline: 32203977]

46. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. N Engl J Med 2003 May 15;348(20):1953-1966. [doi: 10.1056/nejmoa030781]

47. Duszynski TJ, Fadel W, Wools-Kaloustian KK, Dixon BE, Yianoutsos C, Halverson PK, et al. Association of Health Status and Nicotine Consumption with SARS-CoV-2 positivity rates. BMC Public Health 2021 Oct 03;21(1):1786 [FREE Full text] [doi: 10.1186/s12889-021-11867-6] [Medline: 34600513]

48. COVID-19: Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention. URL: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html [accessed 2021-11-23]

49. Pearlson GL, Ganz PA, McGuigan K, Malin JR, Adams J, Kahn KL. The case identification challenge in measuring quality of care. J Clin Oncol 2002 Nov 01;20(21):4353-4360. [doi: 10.1200/JCO.2002.05.527] [Medline: 12409335]

50. Meguerditchian A, Stewart A, Roistacher J, Watroba N, Croppe M, Edge SB. Claims data linked to hospital registry data enhance evaluation of care of breast cancer. J Surg Oncol 2010 Jun 01;101(7):593-599. [doi: 10.1002/jso.21528] [Medline: 20461766]
51. Baldi I, Vicari P, Di Cuonzo D, Zanetti R, Pagano E, Rosato R, et al. A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. J Clin Epidemiol 2008 Apr;61(4):373-379. [doi: 10.1016/j.jclinepi.2007.05.017] [Medline: 18313562]

52. Leung KM, Hasan AG, Rees KS, Parker RG, Legorreta AP. Patients with newly diagnosed carcinoma of the breast: validation of a claim-based identification algorithm. J Clin Epidemiol 1999 Jan;52(1):57-64. [doi: 10.1016/s0895-4356(98)00143-7] [Medline: 9973074]

53. Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol 2009 Dec;95(3):427-431. [doi: 10.1007/s11060-009-9943-z] [Medline: 19562256]

54. Englum BR, Prasad NK, Lake RE, Mayorga-Carlin M, Turner DJ, Siddiqui T, et al. Impact of the COVID-19 pandemic on diagnosis of new cancers: A national multicenter study of the Veterans Affairs Healthcare System. Cancer 2022 Mar 01;128(5):1048-1056 [FREE Full text] [doi: 10.1002/cncr.34011] [Medline: 34866184]

55. Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. The Lancet Oncology 2020 Jun;21(6):750-751. [doi: 10.1016/s1470-2045(20)30265-5]

56. Gurney JK, Millar E, Dunn A, Pirie R, Mako M, Manderson J, et al. The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand-a country pursuing COVID-19 elimination. Lancet Reg Health West Pac 2021 May;10:100127 [FREE Full text] [doi: 10.1016/j.lanwpc.2021.100127] [Medline: 33778794]

57. Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. The Lancet Oncology 2020 Jun;21(6):748-750. [doi: 10.1016/s1470-2045(20)30242-4]

Abbreviations

HIE: health information exchange
HR: hazard ratio
INPC: Indiana Network for Patient Care
STROBE: Strengthening the Reporting of Observational Studies in Epidemiology

©Nimish Valvi, Hetvee Patel, Giorgos Bakoyannis, David A Haggstrom, Sanjay Mohanty, Brian E Dixon. Originally published in JMIR Cancer (https://cancer.jmir.org), 06.10.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on https://cancer.jmir.org/, as well as this copyright and license information must be included.